Sita TL, Petras KG, Wafford QE, Berendsen MA, Kruser TJ. Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review. J Neurooncol. 2017;133(3):531–8.
Article
Google Scholar
Fine SW. Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations. Adv Anat Pathol. 2012;19(4):204–16.
Article
Google Scholar
Cai T, Nesi G, Tinacci G, Giubilei G, Gavazzi A, Mondaini N, et al. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. J Surg Res. 2011;167(2):267–72.
Article
Google Scholar
Chughtai B, Mian BM. High risk prostate cancer: evolving definition and approach to management. Can J Urol. 2008;15(6):4375–80.
Google Scholar
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37. https://doi.org/10.1016/j.eururo.2013.09.046. Epub 2013 Oct 6.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79. https://doi.org/10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
Cho Y, Chang JS, Rha KH, Hong SJ, Choi YD, Ham WS, et al. Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis? PLoS ONE. 2016;11(1): e0147191.
Article
Google Scholar
Macias VA, Barrera-Mellado I. Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial. BJU Int. 2020;125(2):215–25.
Article
Google Scholar
Yuan Y, Zhang Q, Xie C, Wu T. Effect of Salvage Radiotherapy and Endocrine Therapy on Patients with Biochemical Recurrence After Prostate Cancer Operation- a Meta-Analysis. Am J Mens Health. 2021;15(3):15579883211024880.
Article
Google Scholar
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021;19(2):134–43. https://doi.org/10.6004/jnccn.2021.0008.
Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(11):1234–42.
Article
CAS
Google Scholar
Hori M, Murakami T, Kim T, Tomoda K, Nakamura H. CT Scan and MRI in the Differentiation of Liver Tumors. Digestive diseases (Basel, Switzerland). 2004;22(1):39–55.
Article
Google Scholar
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.
Article
CAS
Google Scholar
Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70(6):926–37.
Article
Google Scholar
Kranzbühler B, Müller J, Becker AS, Garcia Schüler HI, Muehlematter U, Fankhauser CD, et al. Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL. J Nucl Med. 2020;61(2):194–201. https://doi.org/10.2967/jnumed.118.225276. Epub 2019 Aug 2.
Grubmüller B, Baltzer P, Hartenbach S, D’Andrea D, Helbich TH, Haug AR, et al. PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(24):6300–7.
Article
Google Scholar
Corfield J, Perera M, Bolton D, Lawrentschuk N. (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol. 2018;36(4):519–27.
Article
Google Scholar
Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, et al. Diagnostic Accuracy of (68)Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology. 2018;289(3):730–7.
Article
Google Scholar
Natarajan A, Agrawal A, Murthy V, Bakshi G, Joshi A, Purandare N, et al. Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients. World journal of nuclear medicine. 2019;18(3):244–50.
Article
Google Scholar
Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, et al. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021;109(1):174–85.
Article
Google Scholar
Zhang YN, Lu ZG, Wang SD, Lu X, Zhu LL, Yang X, et al. Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI. Cancer imaging : the official publication of the International Cancer Imaging Society. 2022;22(1):36.
Article
CAS
Google Scholar
Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–72.
Article
CAS
Google Scholar
Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol. 2007;52(1):29–37.
Article
Google Scholar
Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, et al. Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2019;140:68–75.
Article
Google Scholar
Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2019;17(5):479–505.
White I, Hunt A, Bird T, Settatree S, Soliman H, McQuaid D, et al. Interobserver variability in target volume delineation for CT/MRI simulation and MRI-guided adaptive radiotherapy in rectal cancer. Br J Radiol. 2021;94(1128):20210350.
Article
Google Scholar
Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44(1):92–101.
Article
CAS
Google Scholar
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet (London, England). 2020;395(10231):1208–16.
Article
CAS
Google Scholar
Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmöller L, et al. Prospective comparison of whole-body MRI and (68)Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46(7):1542–50.
Article
CAS
Google Scholar
Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, et al. PSMA-targeted Radiotracers versus (18)F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology. 2020;296(1):44–55.
Article
Google Scholar
Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(9):2978–89.
Article
CAS
Google Scholar
Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, et al. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. European urology oncology. 2022;5(1):100–3.
Article
Google Scholar
Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016;57(11):1713–9.
Article
CAS
Google Scholar
van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119(2):209–15.
Article
Google Scholar
Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, et al. Impact of Staging (68)Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology. 2019;125:154–62.
Article
Google Scholar
Gill BS, Pai SS, McKenzie S, Beriwal S. Utility of PET for Radiotherapy Treatment Planning. PET clinics. 2015;10(4):541–54.
Article
Google Scholar
Lundemann M, Munck Af Rosenschöld P, Muhic A, Larsen VA, Poulsen HS, Engelholm SA, et al. Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. European journal of nuclear medicine and molecular imaging. 2019;46(3):603–13.
Scranton RA, Sadrameli S, Butler EB, Farach A, Wang HC, Teh BS, et al. Coregistration of Magnetic Resonance and [(18)F] Fludeoxyglucose-Positron Emission Tomography Imaging for Stereotactic Radiation Therapy Planning: Case Report in a Previously Irradiated Brain Metastasis With Recurrent Tumor and Radiation Necrosis. Pract Radiat Oncol. 2020;10(2):133–7.
Article
Google Scholar
Lucia F, Visvikis D, Desseroit MC, Miranda O, Malhaire JP, Robin P, et al. Prediction of outcome using pretreatment (18)F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018;45(5):768–86.
Article
Google Scholar
Iizuka Y, Matsuo Y, Umeoka S, Nakamoto Y, Ueki N, Mizowaki T, et al. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET. Eur J Radiol. 2014;83(11):2087–92.
Article
Google Scholar
Nishioka T, Shiga T, Shirato H, Tsukamoto E, Tsuchiya K, Kato T, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys. 2002;53(4):1051–7.
Article
Google Scholar
Evangelista L, Cassarino G, Lauro A, Morlacco A, Sepulcri M, Nguyen AAL, et al. Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer. Abdominal radiology (New York). 2021;46(9):4401–9.
Article
Google Scholar
Liu A, Zhang M, Huang H, Zhang C, Ruan X, Lin W, et al. Clinical Utility of (18)F-PSMA-1007 Positron Emission Tomography/Magnetic Resonance Imaging in Prostate Cancer: A Single-Center Experience. Front Oncol. 2020;10: 612701.
Article
Google Scholar